Değer202020212022202320242025TTMSatış/genel/idari giderler———————Araştırma ve geliştirme———————Faaliyet karı———————Faaliyet Dışı Gelir, Toplam———————Faiz gideri (aktifleştirilmiş faizler düşüldükten sonra)———————Faaliyet Dışı Gelir (Faiz Giderleri Hariç)———————Olağandışı gelirler/giderler———————Vergi öncesi kar———————Kazançlardaki özsermayeler———————Vergiler———————Kontrol gücü olmayan/azınlık payı———————Vergi sonrası diğer gelirler/giderler———————Durdurulan faaliyetler öncesi net kar———————Durdurulan faaliyetler———————Net kar———————Seyreltme ayarlaması———————İmtiyazlı temettüler———————Adi hisse senedi sahiplerine düşen seyreltilmiş net kar———————Temel hisse başına kazanç (Temel EPS)———————Seyreltilmiş hisse başına kazanç (Seyreltilmiş EPS)———————Dolaşımdaki ortalama adi hisse senedi sayısı———————Dolaşımdaki seyreltilmiş hisse senedi sayısı———————FAVÖK———————FVÖK———————Gelir maliyeti———————Satılan malların diğer maliyeti———————Amortisman ve itfa (nakit akışı)———————
Fresenius Medical Care AG American Depositary Shares (Each repr
Fresenius Medical Care AG & Co. KGaA is a German healthcare company which provides kidney dialysis services through a network of 4,171 outpatient dialysis centers, serving 345,425 patients. The company primarily treats end-stage renal disease, which requires patients to undergo dialysis 3 times per week for the rest of their lives.
With a global headquarters in Bad Homburg vor der Höhe, Germany, and a North American headquarters in Waltham, Massachusetts, it has a 38% market share of the dialysis market in the United States. It also operates 42 production sites, the largest of which are in the U.S., Germany, and Japan.
The company is 32% owned by Fresenius and, as of 2020, generates around 50% of the group's revenue.
As of 2024, the company was ranked as #612 on the World's Best Employers list published by Forbes.